[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605773":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":23,"locations":29,"responsibleParty":66,"collaborators":12,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":12,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":12,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":32,"whyStopped":12,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Saglik Bilimleri Universitesi","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Group","NO_INTERVENTION","In the control arm, patients will continue their eating habits.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Gluten Free Diet","EXPERIMENTAL","Patients in the experimental arm will received a gluten-free diet for 8 weeks.",[18],"Behavioral: Gluten Free Diet",[20],{"type":21,"name":14,"description":16,"armGroupLabels":22,"otherNames":12},"BEHAVIORAL",[14],[24],{"name":25,"role":26,"phone":27,"phoneExt":12,"email":28},"Gülay Sezgin","CONTACT","+902124147171","dytgulaysezgin@gmail.com",[30,50,56,61],{"facility":31,"status":32,"city":33,"state":12,"zip":12,"country":34,"countryCode":12,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Bakırköy Dr. Sadi Konuk Training and Research hospital","RECRUITING","Istanbul","Turkey (Türkiye)",{"type":36,"coordinates":37},"Point",[38,39],28.94966,41.01384,{"lat":39,"lon":38},[42,43,46,48],{"name":25,"role":26,"phone":27,"phoneExt":12,"email":28},{"name":44,"role":45,"phone":12,"phoneExt":12,"email":12},"Sibel Çağlar","SUB_INVESTIGATOR",{"name":47,"role":45,"phone":12,"phoneExt":12,"email":12},"Emine I Üstün",{"name":25,"role":49,"phone":12,"phoneExt":12,"email":12},"PRINCIPAL_INVESTIGATOR",{"facility":51,"status":52,"city":33,"state":12,"zip":12,"country":34,"countryCode":12,"cosmosGeoPoint":53,"geoPoint":55,"contacts":12},"İstanbul Medeniyet University","ACTIVE_NOT_RECRUITING",{"type":36,"coordinates":54},[38,39],{"lat":39,"lon":38},{"facility":57,"status":52,"city":33,"state":12,"zip":12,"country":34,"countryCode":12,"cosmosGeoPoint":58,"geoPoint":60,"contacts":12},"İstanbul Sağlık Bilimleri University",{"type":36,"coordinates":59},[38,39],{"lat":39,"lon":38},{"facility":62,"status":52,"city":33,"state":12,"zip":12,"country":34,"countryCode":12,"cosmosGeoPoint":63,"geoPoint":65,"contacts":12},"Marmara University",{"type":36,"coordinates":64},[38,39],{"lat":39,"lon":38},{"type":49,"investigatorFullName":25,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"Dietitian","100605773","the-impacts-of-gluten-free-diet-in-patients-with-ankylosing-spondylitis-100605773",false,"NCT07166874","The Impacts of Gluten-free Diet in Patients With Ankylosing Spondylitis","The Impacts of Gluten Free Diet on Disease Activity, Quality of Life and Intestinal Permeability in Patients Diagnosed With Ankylosing Spondylitis.","Inclusion Criteria:\n\n* diagnosis of axial SpA defined by ASAS criteria\n* Adults (aged 18-64 years)\n* stable treatment (NSAID and\u002For DMARD) for at least 3 months\n* provide written informed consent and submit to the requirements of the study\n\nExclusion Criteria:\n\n* Any diet at the time of inclusion or within 3 months prior to inclusion;\n* have a history of celiac disease;\n* have a history of Ulcerative Colitis, Crohn's Disease and Irritable Bowel Syndrom\n* patients with Type 1 and Type 2 Diabetes Mellitus\n* patients with Hashimoto Thyroiditis\n* are pregnant, breastfeeding,\n* patients who have used omega-3 and vitamins (A, C, E) regularly in the last 3 months.\n* BMI \\\u003C18,50 kg\u002Fm2\n* BMI ≥29,99 kg\u002Fm2","ALL","18 Years","64 Years",{"count":79,"type":80},60,"ESTIMATED","INTERVENTIONAL",[83],"NA","Subclinical intestinal inflammation and intestinal permeability have been reported in patients with ankylosing spondylitis. Gluten is one of the main triggers of zonulin releaseand gluten intake may contribute to the development of the disease by increasing intestinal permeability. This study aims to determine the impacts of a gluten-freediet on intestinal permeability, sub-clinical intestinal inflammation, disease activity, functional status and quality of life in patients with ankylosing spondylitis. The main questions it aims to answer are:\n\nDoes a gluten-free diet have an effect on disease activity and functional status in patients with ankylosing spondylitis? Does a gluten-free diet have an effect on intestinal permeability and subclinical intestinal inflammation in patients with ankylosing spondylitis? The investigators will evaluate the effects of the gluten-free diet compared to a control group.",[86],"Ankylosing Spondylitis",[88,89,90,91,92,93],"gluten free diet","intestinal permeability","zonulin","ankylosing spondylitis","cytokine","BASDAI","2025-09-03",{"date":96,"type":97},"2025-09-10","ACTUAL",{"date":99,"type":97},"2025-01-31",{"date":101,"type":80},"2026-05-31",{"name":5,"class":6},4]